Articles tagged with Oncology
Insilico Medicine will present four novel cancer inhibitors discovered via its Pharma.AI platform, targeting KRAS and Cbl-b pathways. ISM6166 and ISM3830 demonstrate robust anti-tumor activity against solid tumors with KRAS alterations and restored innate and adaptive immunity, respectively.
The NCCN 2026 Annual Conference emphasized the need for holistic care for adolescents and young adults with cancer, highlighting unique challenges and the importance of supportive services. The conference also addressed global cancer care realities and future strategies, emphasizing the need for collaboration and investment to address ...
Roy S. Herbst will lead integrated efforts to strengthen cancer research, education, and collaboration across Dartmouth and Dartmouth Health. He aims to expand access to advanced treatments and clinical trials, elevating cancer care in New England and beyond.
A framework has been developed to identify candidate pathogenic variants hidden among uncertain significance variants detected in comprehensive genomic profiling. The framework was tested using BRCA1 and BRCA2 genes, leading to the classification of a previously unknown variant as pathogenic.
The San Antonio Breast Cancer Symposium generated nearly $40 million in economic impact and drew over 11,000 attendees from 104 countries. The symposium also produced $1.5 million in local tax revenue and supported more than 6,800 jobs.
Researchers used machine learning methods to identify safe time windows for outpatient stem cell therapy in multiple myeloma patients. The study found that this approach can predict adverse events and enable more precise risk assessment.
A new genetic 'roadmap' provides a navigational framework for more precise diagnosis and treatment of intrahepatic cholangiocarcinoma. The framework identifies five molecular subtypes, each associated with distinct therapeutic vulnerabilities, enabling targeted treatment strategies.
Dr. Lisa G. Roth, MD has joined Hassenfeld Children’s Hospital at NYU Langone and Perlmutter Cancer Center as director of the Division of Pediatric Hematology-Oncology. She will oversee clinical care, research, and education programs while expanding access to advanced therapies and clinical trials.
A newly developed AI tool called EvORanker analyzes genetic patterns across over 1,000 species to identify the cause of rare diseases. In clinical testing, it successfully identified the disease-causing gene in nearly 70% of cases, offering new hope for treatment and closure.
Researchers developed AI models to analyze conversations between children with cancer and their caregivers, detecting severe symptoms that require extra support. More complex prompting strategies outperformed simpler ones in accurately identifying symptom severity and its impact.
The BiliSeq test detected approximately 82% of bile duct cancers, compared to 44% with pathology alone, and increased cancer detection to nearly 90% when combined with pathology. This improved accuracy enables physicians to provide more personalized medicine and treatment options for patients.
A new study reveals that excess weight can physically enlarge organs, creating more opportunities for cancer to take hold. The study found that organs grew larger as body weight increased, with the liver growing by 12%, kidneys by 9%, and pancreas by 7% for every 5-point increase in BMI.
A £43M EU-funded initiative, COMPASS, aims to detect heart-related risks in cancer patients and survivors using innovative medical and digital technologies. The project will develop AI-powered clinical pathways to enhance cardiotoxicity detection, safer treatment, and better long-term cardiovascular outcomes.
Researchers have reported early, reassuring results from the LORD trial on active surveillance for low-risk DCIS. The study found that patients with active surveillance did not experience worse early outcomes compared to those who underwent immediate surgery, and that many chose active surveillance over surgery.
Researchers developed an AI model that analyzes routine pathology slides to predict breast cancer recurrence and chemotherapy benefit. The model was validated in a large clinical trial and demonstrates fast, accessible, and globally scalable diagnostic capabilities.
Researchers found that combining targeted radiation therapy with BO-112 and anti-PD-1 therapy before surgery activated the immune system to fight cancer. This approach reshaped the tumor microenvironment to support T-cell activity, resulting in fewer cancer cells and a more effective anti-tumor response.
A recent study published in JAMA Oncology suggests that obesity control is a potentially effective strategy for cancer prevention. The research reveals that successful weight management can lead to a significant reduction in the risk of various cancers, making it an underutilized approach in cancer prevention.
Researchers found that NUTM1 rearranged leukemia is distinct from other forms, with decreased DNA methylation and increased lifespan of blood cells. Leukemias with BRD9-NUTM1 fusion are extremely sensitive to chemotherapy, leading to improved clinical outcomes.
A study found CREB5 regulates basal and SCL transcriptional programs and tumor-forming phenotypes in prostate cancer, suggesting a central role in aggressive prostate cancer. Disrupting CREB5-regulated pathways may improve therapeutic responses in advanced disease.
A recent study found that breast cancer recurrence remains low even after ten years when patients receive tailored radiotherapy. The research involved 848 patients who underwent chemotherapy and surgery, and showed that radiotherapy can be reduced or eliminated in low-risk patients, leading to a significant decrease in side effects.
A systematic review highlights the biological mechanisms linking chronic stress to cancer course, including HPA axis activation and immune suppression. Chronic stress affects tumor growth, treatment resistance, and patient outcomes differently across various cancers.
The European project CGI-Clinics brings AI-powered Cancer Genome Interpreter (CGI) closer to clinical applications, enabling reliable and scalable tumour genome interpretation in precision oncology. The platform leverages machine learning to transform complex genomic data into actionable insights.
A study found that cancer patients during the last phase of life experienced more bleeding events than thromboembolic events. Most patients continued their antithrombotic therapy despite increased bleeding risk, with over 28% experiencing at least one bleeding episode.
UCLA researchers identified a key protein, E2F3, essential for survival in cancer cells lacking the protective gene RB. Blocking E2F3 effectively halted tumor growth, offering a new strategy for treating aggressive cancers.
A minimally invasive liquid biopsy test has been shown to diagnose Burkitt lymphoma rapidly and accurately in sub-Saharan Africa, where delays in traditional testing often prove fatal. The test achieved an overall accuracy of 98% and reduced the time needed to reach a diagnosis by 40 days on average.
A novel method for monitoring on-treatment disease burden in high-grade serous ovarian cancer uses tumor-informed breakpoints-spanning ddPCR, detecting superior sensitivity and specificity compared to real-time PCR. The approach may enable sensitive and specific detection of minimal residual disease and early relapse detection.
The Society for Maternal-Fetal Medicine has released the first evidence-based clinical guidance for cancer diagnosis and treatment during pregnancy. The guidance aims to support both maternal health and pregnancy goals, while also prioritizing effective cancer therapy and fetal well-being.
Researchers engineered Escherichia coli Nissle 1917 bacteria to produce anticancer agent Romidepsin, which was released from the bacteria and effectively targeted cancer cells in mouse models. The study establishes a solid foundation for bacteria-assisted tumor-targeted therapy, paving the way for future advancements in cancer treatment.
Dr. Aliesha O’Raw, Principal Investigator at TIBI and Co-Founder of OnVagus, has been selected for the 2026 ACS BrightEdge Entrepreneurs Program. The program provides mentorship, entrepreneur training, and early-stage investment support to advance cancer diagnostic and therapeutic solutions.
Impact Journals is exhibiting at the AACR Annual Meeting 2026 in San Diego, showcasing recent publications and discussing collaboration opportunities. The meeting highlights the latest advances in cancer science and medicine, with a focus on research impact, ethical standards, and scientific integrity.
A new clinical trial will investigate whether adding the oral medication vorasidenib to standard chemotherapy improves progression-free survival for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma. The study aims to recruit 400 individuals with this type of brain cancer and evaluate the safety and side-effect profile of the...
A cross-sectional analysis found significant delays in treatment initiation for early-onset colorectal cancer in all-urban populations, with young male, Asian or Pacific Islander, Black, or Hispanic patients disproportionately affected. These delays, exceeding 90 days, challenge assumptions of uniformly timely access in urban settings.
A recent study found that women have a 21% lower risk of death compared to men, but a 12% higher risk of severe side effects from cancer treatment. The research, conducted in partnership with international collaborators, analyzed data from over 20,000 cancer patients and identified sex-based differences in survival and treatment toxicity.
A new study found that A&E patients with visible blood in their urine who receive a scan within 48 hours are 2.5% less likely to die within three months. The study also showed that patients with cancer are diagnosed significantly faster when they receive prompt investigation.
Researchers compare prostate cancer screening to breast cancer screening, finding similarities in identifying significant cancers and reducing mortality. The study suggests that prostate cancer screening should be reconsidered, offering benefits over harms, and highlights the need for further analysis on costs.
A new study found that bilingual consent forms significantly improve cancer treatment understanding among people with limited English, with understanding rising from 35% to 60%. The study, published in Supportive Care in Cancer, examined the impact of different translation approaches on cancer treatment understanding among Bengali- and...
A new study by UCLA researchers shows that a personalized counseling program, called Motivation and Problem-Solving (MAPS), can help cervical cancer survivors quit smoking, with twice as many women quitting compared to standard support. The program's cost-effectiveness is also demonstrated, with the probability of being cost-effective ...
A new imaging test, PSMA PET/CT scan, has been shown to safely reduce the number of biopsies needed for suspected prostate cancer, with no harm to patients. The PRIMARY2 trial found that the scan could identify low-risk patients who did not need a biopsy, while targeting suspicious areas for those who did.
Researchers found that patients who followed an exercise prescription while receiving chemotherapy reported fewer problems with thinking and memory and felt less mentally tired. The study suggests that exercise may help people with cancer stay mentally sharp and better able to handle daily tasks.
Researchers developed an experimental therapy to target microscopic precancerous lesions in the pancreas, which nearly doubled survival in mouse models of pancreatic ductal adenocarcinoma. Long-term treatment with the therapy tripled median overall survival time compared to untreated mice.
Research presented at EAU26 confirms that prostate cancer screening leads to a reduction in mortality, but also detects cancers that would otherwise remain undetected. The study's findings suggest that using MRI in prostate cancer screening can reduce overdiagnosis and unnecessary biopsies.
Severe COVID-19 and influenza infections can prime the lungs for cancer development, according to new research. Vaccination, however, largely prevents these changes, suggesting a reduced risk of lung cancer.
A new study found that MYC amplification in metastatic prostate cancer is associated with reduced tumor immunogenicity, making it harder for the immune system to detect and attack the tumor. This reduction in immunogenicity was linked to poorer progression-free survival outcomes in patients with MYC-amplified tumors.
The Alliance trial explores the combination of zanubrutinib and sonrotoclax for CLL treatment, aiming to send cancer into remission and allow patients to stop treatment earlier. The study has the potential to be life-changing for patients and their families, reducing the burden of ongoing therapy and improving quality of life.
Singapore's breast cancer incidence is rising, but mortality rates are falling, mirroring global trends. The country's strong healthcare system and high-screening participation have contributed to improved survival rates.
The Alliance for Clinical Trials in Oncology is spotlighting new trials for colorectal cancer in March, focusing on early detection methods and treatments for treatment delays and loss of appetite. The trials aim to improve patient outcomes, with several enrolling patients with newly diagnosed colon or rectal cancer.
A new case report describes a large, calcified solid pseudopapillary neoplasm of the pancreatic head, emphasizing the importance of multidisciplinary evaluation and long-term follow-up for monitoring recurrence. The case underscores the diagnostic value of integrating imaging, histopathology, and immunohistochemistry.
A new clinical study aims to improve communication between patients and families about genetic risks of colorectal cancer. The trial will compare two methods of sharing genetic test results with close relatives, with the goal of learning which approach helps more family members get necessary genetic testing.
A study found that only 9% of older adults with advanced cancer prioritize extending survival over maintaining quality of life. The lack of responsiveness of the current oncology care delivery system to patient preference may be a significant issue. This highlights the need for care system changes to prioritize patient needs.
Researchers developed an AI-based liquid biopsy test that detects early liver fibrosis and cirrhosis, and reveals signals of broader chronic disease burden. The test uses genome-wide cell-free DNA fragmentation patterns and repeat landscapes to identify disease-specific signatures.
The novel approach outperforms standard CAR-T cell therapy in preclinical studies using mouse models of glioblastoma and ovarian cancer. Armored CAR-T cells eliminate tumors, reshape the tumor environment, and boost immune-cell activity.
New research warns that popular AI systems for predicting cancer biology may rely on visual shortcuts, raising concerns about their reliability for real-world patient care. Despite achieving high accuracy, these models often fail when conditions change or confounding factors are controlled.
Researchers developed CAR macrophages that crossed the blood-brain barrier, recognizing and destroying cancer cells and releasing signals to harm nearby tumors. The treatment showed significant reductions in brain tumor progression and increased survival in preclinical models.
The ORIGIN study uses advanced molecular tools to identify risk factors and early warning signals in stored blood samples from up to 13,000 service members. By analyzing these data, researchers aim to predict and prevent diseases such as cancer, heart disease, and autoimmune disorders years before symptoms appear.
A new UCLA study suggests that adding hormone therapy to post-operative radiotherapy may provide little survival benefit for most men with prostate cancer, especially those with low PSA levels. However, men with higher PSA levels before radiation may see modest improvements in survival and metastasis-free survival.
The article summarizes updated recommendations on fertility preservation in people with cancer, considering potential health risks to offspring and treatment side effects. Clinicians should inform patients about available options before treatment initiation.
The Alliance for Clinical Trials in Oncology will host a webinar highlighting recent clinical advances in breast cancer, multiple myeloma, and leukemia. Researchers will present key findings from ASH and SABCS meetings, impacting treatment outcomes.
A University of Lausanne research team discovered vitamin B7's role in bypassing glutamine addiction in cancer cells. The study found that pyruvate, enabled by pyruvate carboxylase and vitamin B7, fuels cells' energy cycle even without glutamine.
Tumor-infiltrating lymphocytes (TIL) therapy is a form of immunotherapy that harnesses the body's natural defenses to fight cancer. Researchers at Ochsner MD Anderson have successfully treated advanced melanoma using this innovative approach, with many patients experiencing tumor shrinkage or elimination after treatment.
A recent study published in CANCER found that adults with cancer who developed mental health conditions within the first year after diagnosis had a significantly higher likelihood of dying over the next few years. The analysis of data from University of California-affiliated hospitals revealed a 51% increased risk of death among those ...